Amide derivatives of xylopic acid: synthesis and assessment of antiproliferative activity against colorectal cancer
Colorectal cancer (CRC) continues to impose a major global health burden. To overcome current treatment limitations, discovering novel molecular scaffolds is imperative. Herein, we explored the modification of the bioactive natural product xylopic acid (XA 1 ) by synthesizing a library of novel C-19 amide derivatives and assessing their antiproliferative effects in CRC cell lines. This transformation substantially enhanced the cytotoxic potency across the synthesized compounds, with structure-activity relationships highlighting that aromatic moieties, particularly with fluorine substituents, were decisive for biological activity. The difluorinated derivative 12 emerged as the most potent compound across the tested CRC cell lines, showing an IC 50 value of 6.4 μM against SW620 cells, approximately 14-fold greater potency than XA 1 , and a selectivity index of 2.33 toward cancer cells over normal colon epithelial cells (NCM460). Further biological studies indicated that compound 12 halts SW620 cell proliferation primarily via a cytostatic mechanism, inducing G0/G1 cell cycle delay. This effect was accompanied by modulation of cell-cycle regulatory proteins, including reduced CDK4 and CDK6 expression, suppressed mTOR activation, and alterations in intracellular ROS dynamics. Docking analyses provided a structural hypothesis consistent with potential interaction of compound 12 with the CDK4 ATP-binding pocket. Overall, these results identify XA 1 amide derivatives as promising antiproliferative scaffolds and establish compound 12 as a starting point for further development against CRC.
Authors
- Silvia Marín (ORCID: https://orcid.org/0000-0003-0693-2207)
- Jorge A. R. Salvador (ORCID: https://orcid.org/0000-0003-0779-6083)
- Rita I. Oliveira (ORCID: https://orcid.org/0000-0002-1511-4364)
- Pedro J. M. Sobral (ORCID: https://orcid.org/0000-0001-5202-4002)
- Marta Cascante (ORCID: https://orcid.org/0000-0002-2062-4633)
Institutions
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Institut de Biomedicina de la Universitat de Barcelona (ES)
- Centro de Neurociências e Biologia Celular (PT)
- Centro de Inovação em Biomedicina e Biotecnologia (PT)
- Universitat de Barcelona (ES)
- University of Coimbra (PT)
Publication Details
- Journal
- Frontiers in Chemistry
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fchem.2026.2020526
- Primary Topic
- Heterocyclic Compound Synthesis and Bioactivity
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Generalitat de Catalunya
- Institució Catalana de Recerca i Estudis Avançats
- Ministerio de Ciencia e Innovación
- Universidade de Coimbra
- Universitat de Barcelona
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- Fundação para a Ciência e a Tecnologia
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
- European Regional Development Fund
- Agencia Estatal de Investigación